The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Omega-3 effects on mood, personality, and behavior

    There’s growing interest in the relationship between fatty acids and variability in mood, behavior, and personality.

    Here are the findings of a study conducted by researchers at the department of psychiatry at the University of Pittsburgh in the US.

    Blood levels of alpha-linolenic (alpha-LNA), eicosapentaenoic (EPA), and docosahexaenoic acid (DHA) were measured in 105 adults with high cholesterol blood levels. Mood was measured by using a series of surveys.

    Higher blood levels of EPA and DHA were associated with affect regulation, personality, and impulse control.

    These results are at odds with a literature review published in December 2006 by researchers at the University of Bristol in the UK. They concluded, “The evidence available provides little support for the use of n-3 PUFAs [polyunsaturated fatty acids] to improve depressed mood.”

    Another analysis of the literature concluded there was a “significant benefit in unipolar and bipolar depression.” However, these researchers from the University of Arizona caution, “The results were highly heterogeneous, indicating that it is important to examine the characteristics of each individual study to note the differences in design and execution.”

    They found less evidence of benefit in schizophrenia, and negligible risks with some potential benefit in major depressive and bipolar disorders. The results, they concluded, are inconclusive in most areas of interest in psychiatry.

    The bottom line?
    We haven’t reached the bottom line yet.

    3/27/07 22:50 JR

    Leave a Comment

    You must be logged in to post a comment.